Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

441. Rosuvastatin: do we need another statin?

Rosuvastatin: do we need another statin? Rosuvastatin: do we need another statin? Rosuvastatin: do we need another statin? Ho C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ho C. Rosuvastatin: do we need another statin? Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation (...) . No information on the regulatory status in Canada is currently available. - Limited evidence from small clinical trials suggests that rosuvastatin may produce larger dose-dependent decreases in total cholesterol levels and low-density lipoprotein-cholesterol levels in hypercholesterolemic patients compared to other statins. There is insufficient evidence to draw conclusions about the safety of rosuvastatin. - The impact of rosuvastatin therapy on cardiac morbidity and mortality is not known. More experience

Health Technology Assessment (HTA) Database.2001

442. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. 11430324 2001 06 14 2001 07 05 2016 08 03 0028-4793 344 26 2001 Jun 28 The New England journal of medicine N. Engl. J. Med. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. 1959-65 Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk (...) of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. The rates of coronary events increased

NEJM2001

443. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. 11434828 2001 07 03 2001 07 26 2016 10 17 0098-7484 286 1 2001 Jul 04 JAMA JAMA Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. 64-70 Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk, and retrospective (...) studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may lower CRP in a manner largely independent of low-density lipoprotein cholesterol (LDL-C). However, prospective trial data directly evaluating this anti-inflammatory effect of statins are not available. To test the hypothesis that pravastatin has anti-inflammatory effects as evidenced by CRP reduction. Community-based, prospective, randomized, double-blind trial including 1702 men and women with no prior

JAMA2001

444. Statins for the reduction of risk of Alzheimer's disease.

Statins for the reduction of risk of Alzheimer's disease. BACKGROUND: : Two recent clinical reports describe an association between statin therapy and a reduction in the occurrence of Alzheimer's disease by as much as 70 %. One report is a cross-sectional analysis of discharges among three hospitals, and the other is a nested case control study drawn from ambulatory patients of general practitioners in the UK. Because neither study is a randomized trial, the association noted between statin (...) therapy and a reduced incidence of Alzheimer's disease may have occurred because other factors, unaccounted for in the studies, may be present (so called bias) and be responsible for the observed association. However, there is an expanding body of biological and epidemiological data that makes it plausible that statin therapy may retard or prevent the pathogenesis and clinical expression of Alzheimer's disease. This review was initiated in order to find other clinical evidence that might support

Cochrane2001

445. Statins for the prevention of Alzheimer's disease.

Statins for the prevention of Alzheimer's disease. BACKGROUND: : Two recent clinical reports describe an association between statin therapy and a reduction in the occurrence of Alzheimer's disease by as much as 70 %. One report is a cross-sectional analysis of discharges among three hospitals, and the other is a nested case control study drawn from ambulatory patients of general practitioners in the UK. Because neither study is a randomized trial, the association noted between statin therapy (...) and a reduced incidence of Alzheimer's disease may have occurred because other factors, unaccounted for in the studies, may be present (so called bias) and be responsible for the observed association. However, there is an expanding body of biological and epidemiological data that makes it plausible that statin therapy may retard or prevent the pathogenesis and clinical expression of Alzheimer's disease. This review was initiated in order to find other clinical evidence that might support or refute

Cochrane2001

446. Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy

Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy Berto P, Munro V, Gaddi A, Negrini C, Hutton J, Mast O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two dosage regimens (0.2 and 0.4 mg/day) of cerivastatin against two other statins, simvastatin and pravastatin, in the primary prevention of coronary heart disease (CHD). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.2000

447. Clinical outcomes in statin treatment trials: a meta-analysis

Clinical outcomes in statin treatment trials: a meta-analysis Clinical outcomes in statin treatment trials: a meta-analysis Clinical outcomes in statin treatment trials: a meta-analysis Ross S D, Allen I E, Connelly J E, Korenblat B M, Smith M E, Bishop D, Luo D Authors' objectives To determine the risk of cardiovascular events and death in patients receiving statin treatment for cholesterol regulation. Searching The authors searched MEDLARS using the search terms: 'anticholesterolemic agents (...) , French, German, Spanish or Italian. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) with parallel design and duration of at least one year. Eligible studies had to have at least 10 participants per group and one group receiving a monotherapy statin agent versus at least one concurrent control arm that used placebo or no pharmacologic treatment for cholesterol regulation. Specific interventions included in the review Statin treatment (lovostatin

DARE.1999

448. What role for statins: a review and economic model

What role for statins: a review and economic model What role for statins: a review and economic model What role for statins: a review and economic model Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon T A, Lampe F, Sampson F, Ward S, Wannamethee G Authors' objectives The review aimed to answer the following questions: 1. By how much do low fat and other diets reduce blood cholesterol? And how effective are such effects in reducing coronary heart disease (CHD) risk? 2. Does (...) treatment with statins reduce CHD events and are relative reductions in these events independent of the level of CHD risk? 3. How effective are non-cholesterol lowering drug treatments (i.e. aspirin, beta-blockers, and antihypertensives) for reducing CHD risk relative to dietary modifications and cholesterol lowering drug treatments? 4. What is the relative cost-effectiveness of different approaches to reducing cholesterol and/or CHD? Searching MEDLINE and the Cochrane CENTRAL Register were searched

DARE.1999

449. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials LaRosa J C, He J, Vupputuri S Authors' objectives To estimate the reduced risk of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women (...) . Searching MEDLINE was searched from 1966 to December 1998 using the following MeSH: 'hydroxy-methyl-glutaryl-CoA reductase inhibitors', 'simvastin', 'lovastatin', 'pravastatin', 'coronary disease' and 'myocardial infarction'. In addition, the keywords 'statin' and 'coronary heart disease' were used. The search was restricted to those studies conducted in human participants, published in English language journals, and classified as clinical trials in the MEDLINE database. A manual search was also

DARE.1999

450. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment Pickin D M, McCabe C J, Ramsay L E, Payne N, Haq I U, Yeo W W, Jackson P (...) R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) treatment in subgroups of the population at different levels of coronary heart disease (CHD) risk. Type

NHS Economic Evaluation Database.1999

451. What role for statins? A review and economic model

What role for statins? A review and economic model What role for statins? A review and economic model What role for statins? A review and economic model Ebrahim S, Davey Smith G, McCabe D, Payne N, Pickin M, Sheldon TA, Lampe F, Sampson F. Ward S, Wannamethee G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ebrahim S, Davey Smith G (...) , McCabe D, Payne N, Pickin M, Sheldon TA, Lampe F, Sampson F. Ward S, Wannamethee G. What role for statins? A review and economic model. Health Technology Assessment 1999; 3(19): 1-91 Authors' objectives This review aimed to answer the following questions: 1. By how much do low fat and other diets reduce blood cholesterol, and how effective are they in reducing CHD risk? 2. Does treatment with statins reduce CHD events and are relative reductions in these events independent of the level of CHD risk? 3

Health Technology Assessment (HTA) Database.1999

452. What role for statins? A review and economic model

What role for statins? A review and economic model What role for statins? A review and economic model Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0

NIHR HTA programme1999

453. Cost-effectiveness of statins

Cost-effectiveness of statins Cost-effectiveness of statins Cost-effectiveness of statins Huse D M, Russell M W, Miller J D, Kraemer D F, D'Agostino R B, Ellison R C, Hartz S C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology (...) use data were collected from studies published between 1992 and 1998. Cost data were collected from studies published between 1986 and 1998. The price year was not reported. Source of effectiveness data Effectiveness data were derived from a review of the literature. Coronary heart disease event occurrence was derived from the Framingham Heart Study (using coronary health risk appraisal functions). The effectiveness of statin therapy was derived using approved US Food and Drug Administration

NHS Economic Evaluation Database.1998

454. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.

The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. 9420339 1998 01 08 1998 01 08 2013 11 21 0028-4793 338 2 1998 Jan 08 The New England journal of medicine N. Engl. J. Med. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. 86-93

NEJM1998

455. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials

Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials Hebert P R, Gaziano J M, Chan K S, Hennekens C H Authors' objectives To assess the effectiveness of statin drugs to reduce the risk of stroke and total mortality (...) . Searching A computerised literature search was performed from 1985 to 1995. Data from the Cholesterol and Recurrent Events (CARE) Trial was added when the report was published in late 1996. The search was limited to English language articles. Principal researchers of the included trials and their respective funding bodies were contacted for details of unpublished reports. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) testing statin drugs with

DARE.1997

456. Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors Blauw G J, Lagaay A M, Smelt A H, Westendorp R G Authors' objectives To estimate (...) the effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors ('statins') on stroke risk. Searching MEDLINE was searched from 1980 to 1996, and Current Contents (Life Sciences) from January through May 1996. The search strategy used the terms 'HMG-CoA reductase inhibitor', 'lovastatin', 'simvastatin', 'pravastatin', 'fluvastatin', 'atorvastatin', 'randomized controlled trial' (RCT), and 'double-blind method', both as MeSH and textwords. Reviews and preliminary reports were searched

DARE.1997

457. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing (...) coronary heart disease: life table method applied to health authority population Pharoah P D, Hollingworth W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of statins to lower cholesterol concentration in patients

NHS Economic Evaluation Database.1996